Á¦³×¸¯ ÀǾàǰ ½ÃÀå - ¼¼°è »ê¾÷ ±Ô¸ð, Á¡À¯À², µ¿Çâ, ±âȸ, ¿¹Ãø, À¯Çüº°, ¿ëµµº°, ¾à¹°Àü´Þº°, Çüź°, °ø±Þ¿øº°, À¯Åë ä³Îº°, Áö¿ªº°, °æÀﺰ ¿¹Ãø(2020-2030³â)
Generic Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By Drug Delivery, By Form, By Source, By Distribution Channel, By Region and Competition, 2020-2030F
»óǰÄÚµå : 1778884
¸®¼­Ä¡»ç : TechSci Research
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 185 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,297,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 5,500 £Ü 7,696,000
PDF and Excel (Multi-User License) help
PDF ¹× Excel º¸°í¼­¸¦ ±â¾÷ÀÇ ÆÀÀ̳ª ±â°ü¿¡¼­ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,000 £Ü 11,195,000
PDF and Excel (Custom Research License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù. 80½Ã°£ÀÇ ¾Ö³Î¸®½ºÆ® ŸÀÓÀÌ Æ÷ÇԵǾî ÀÖ°í Copy & Paste °¡´ÉÇÑ PPT ¹öÀüµµ Á¦°øµË´Ï´Ù. ªÀº Bespoke ¸®¼­Ä¡ ÇÁ·ÎÁ§Æ® ¼öÇà¿¡ ¸Â´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Á¦³×¸¯ ÀǾàǰ ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 4,434¾ï 4,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, ¿¹Ãø ±â°£À¸·Î´Â 2030³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 6.27%·Î ¾ÈÁ¤µÈ ¼ºÀåÀÌ ¿¹ÃøµË´Ï´Ù.

¼¼°è Á¦³×¸¯ ÀǾàǰ ½ÃÀåÀº ¸¸¼º Áúȯ Áõ°¡, ÀÇ·áºñ Áõ°¡, Àú·ÅÇÑ Ä¡·á ¿É¼ÇÀÇ Çʿ伺 µî ¸î °¡Áö ÁÖ¿ä ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Á¦³×¸¯ ÀǾàǰÀº ¿À¸®Áö³Î ÀǾàǰÀ» ´ëüÇÒ ¼ö ÀÖ´Â ºñ¿ë È¿À²ÀûÀÎ ´ë¾ÈÀ» Á¦°øÇÏ¿© ´õ ¸¹Àº »ç¶÷µéÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. ¿À¸®Áö³Î ÀǾàǰÀÇ Æ¯Çã°¡ ¸¸·áµÇ¸é Á¦³×¸¯ Á¦¾à»ç°¡ ½ÃÀå¿¡ ÁøÀÔÇÒ ¼ö ÀÖ´Â ±âȸ°¡ »ý±â°í, °æÀïÀÌ Ä¡¿­ÇØÁ® °¡°ÝÀÌ Ç϶ôÇÕ´Ï´Ù. ÀÇ·áºñ Àý°¨À» À§ÇØ Á¦³×¸¯ ÀǾàǰ »ç¿ëÀ» Àå·ÁÇÏ´Â Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê´Â ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀÔ´Ï´Ù. »ý¹°ÇÐÀû Á¦Á¦ÀÇ Á¦³×¸¯ ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ½ÅÈï ½ÃÀåÀÇ Á¦³×¸¯ ÀǾàǰ »ý»ê ´É·Â È®´ëµµ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¼¼°è Á¦³×¸¯ ÀǾàǰ ½ÃÀåÀº Àú·ÅÇÑ °¡°Ý, Á¢±Ù¼º, ½ÃÀå °æÀïÀ¸·Î ÀÎÇØ Áö¼ÓÀûÀÎ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. Á¦³×¸¯ ÀǾàǰ°ú ¹ÙÀÌ¿À½Ã¹Ð·¯°¡ ¹Ì±¹ Àüü ÀÇ·áºñ ÁöÃâ¿¡¼­ Â÷ÁöÇÏ´Â ºñÁßÀº 1.2%¿¡ ºÒ°úÇØ ºñ¿ë ´ëºñ È¿À²¼ºÀÌ ¶Ù¾î³³´Ï´Ù.

½ÃÀå °³¿ä
¿¹Ãø ±â°£ 2026-2030³â
½ÃÀå ±Ô¸ð : 2024³â 4,434¾ï 4,000¸¸ ´Þ·¯
½ÃÀå ±Ô¸ð : 2030³â 6,408¾ï 8,000¸¸ ´Þ·¯
CAGR : 2025-2030³â 6.27%
±Þ¼ºÀå ºÎ¹® ÀúºÐÀÚ Á¦³×¸¯ ÀǾàǰ
ÃÖ´ë ½ÃÀå ºÏ¹Ì

½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ

ºñ¿ë È¿À²ÀûÀ̰í Àú·ÅÇÑ °¡°Ý

½ÃÀå °úÁ¦

±ÔÁ¦ Àå¾Ö¹° ¹× ½ÂÀÎ ÀýÂ÷

ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦³×¸¯ »ý¹°ÇÐÀû Á¦Á¦(¹ÙÀÌ¿À½Ã¹Ð·¯)ÀÇ Áøº¸

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå °í°´ÀÇ ¼Ò¸®

Á¦5Àå ¼¼°èÀÇ Á¦³×¸¯ ÀǾàǰ ½ÃÀå Àü¸Á

Á¦6Àå ºÏ¹ÌÀÇ Á¦³×¸¯ ÀǾàǰ ½ÃÀå Àü¸Á

Á¦7Àå À¯·´ÀÇ Á¦³×¸¯ ÀǾàǰ ½ÃÀå Àü¸Á

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Á¦³×¸¯ ÀǾàǰ ½ÃÀå Àü¸Á

Á¦9Àå ³²¹ÌÀÇ Á¦³×¸¯ ÀǾàǰ ½ÃÀå Àü¸Á

Á¦10Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Á¦³×¸¯ ÀǾàǰ ½ÃÀå Àü¸Á

Á¦11Àå ½ÃÀå ¿ªÇÐ

Á¦12Àå ½ÃÀå µ¿Çâ°ú ¹ßÀü

Á¦13Àå PorterÀÇ Five Forces ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

Á¦15Àå Àü·«Àû Á¦¾È

Á¦16Àå ȸ»ç ¼Ò°³ ¹× ¸éÃ¥Á¶Ç×

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Generic Drugs Market was valued at USD 443.44 Billion in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 6.27% through 2030. The Global Generic Drugs Market is primarily driven by several key factors, including the rising prevalence of chronic diseases, increasing healthcare costs, and the need for affordable treatment options. Generic drugs offer a cost-effective alternative to brand-name medications, making them accessible to a broader population. Patent expirations of branded drugs create opportunities for generic manufacturers to enter the market, leading to increased competition and lower prices. Government initiatives promoting the use of generic drugs to reduce healthcare expenditures further fuel market growth. The growing demand for generic versions of biologic drugs and the expansion of generic drug manufacturing capabilities in emerging markets also contribute to the market's expansion. The Global Generic Drugs Market is poised for sustained growth driven by affordability, accessibility, and market competition. Generics and biosimilars represent just 1.2% of total U.S. healthcare spending, underscoring their cost-effectiveness.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 443.44 Billion
Market Size 2030USD 640.88 Billion
CAGR 2025-20306.27%
Fastest Growing SegmentSmall Molecule Generics
Largest MarketNorth America

Key Market Drivers

Cost-effectiveness and Affordability

The affordability and accessibility of generic drugs compared to their brand-name counterparts constitute a pivotal factor driving their widespread adoption and market expansion on a global scale. Generic medications, renowned for their lower price points, serve as indispensable alternatives for patients and healthcare systems grappling with constrained budgets or exorbitant out-of-pocket expenses associated with branded pharmaceuticals. In regions where healthcare resources are scarce or where patients bear a substantial burden of medication costs, the cost-effectiveness of generic drugs emerges as a cornerstone of healthcare provision. The considerable price differentials between generic and brand-name medications facilitate broader access to essential treatments, ensuring that individuals can afford the medications they need to manage their health conditions effectively.

A fundamental driver of the cost-effectiveness of generic drugs lies in the expiration of patents on brand-name medications. Upon patent expiry, generic manufacturers gain the legal right to produce and distribute equivalent versions of the drug, igniting competition within the pharmaceutical market. This competitive landscape fosters price reductions as generic manufacturers leverage economies of scale, streamlined production processes, and reduced research and development costs to offer their products at significantly lower prices.

Key Market Challenges

Regulatory Hurdles and Approval Processes

One of the primary challenges confronting the Global Generic Drugs Market is navigating the complex regulatory landscape governing generic drug approval processes. Regulatory agencies worldwide, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others, enforce stringent standards and requirements for the approval of generic medications. Generic manufacturers must demonstrate bioequivalence, pharmaceutical equivalence, and therapeutic equivalence to the reference brand-name drug through comprehensive analytical and clinical studies. The regulatory pathway for generic drug approval often entails navigating intricate legal frameworks, conducting extensive pharmacokinetic and pharmacodynamic studies, and adhering to stringent quality assurance standards, all of which pose formidable barriers to entry for manufacturers. Disparities in regulatory requirements between different regions and countries necessitate meticulous compliance with diverse regulatory mandates, adding complexity and uncertainty to the generic drug approval process.

Key Market Trends

Advancements in Generic Biologics (Biosimilars)

The emergence of biosimilars heralds a transformative paradigm shift within the pharmaceutical landscape, ushering in a new era of accessibility, affordability, and innovation in biologic drug therapy. Biosimilars, colloquially referred to as generic versions of biologic drugs, constitute a rapidly burgeoning segment of the generic drugs market, poised to revolutionize the treatment landscape across a diverse array of therapeutic domains. This paradigmatic evolution is underpinned by significant advancements in biotechnology and regulatory frameworks governing biosimilar approval, which collectively catalyze the development, commercialization, and widespread adoption of biosimilar therapies as compelling alternatives to their costly brand-name counterparts. In 2023, the average out-of-pocket cost for a generic drug was USD 7.05, compared to $27.10 for a brand-name drug.

The ascendancy of biosimilars as a burgeoning force within the generic drugs market is predicated upon the intricate interplay between scientific innovation and regulatory harmonization. Pioneering breakthroughs in biotechnological methodologies have empowered manufacturers to elucidate the complex structural and functional attributes of biologic drugs with unparalleled precision and fidelity, thereby facilitating the rational design and engineering of biosimilar formulations that closely mimic the reference biologic products. Leveraging state-of-the-art analytical techniques, manufacturers can meticulously characterize the physicochemical properties, pharmacokinetic profiles, and immunogenicity profiles of biosimilars, ensuring their comparability to the reference biologic drugs with utmost rigor and scientific rigor.

Key Market Players

Report Scope:

In this report, the Global Generic Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Generic Drugs Market, By Type:

Generic Drugs Market, By Application:

Generic Drugs Market, By Drug Delivery:

Generic Drugs Market, By Form:

Generic Drugs Market, By Source:

Generic Drugs Market, By Distribution Channel:

Generic Drugs Market, By Region:

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Generic Drugs Market.

Available Customizations:

Global Generic Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Generic Drugs Market Outlook

6. North America Generic Drugs Market Outlook

7. Europe Generic Drugs Market Outlook

8. Asia-Pacific Generic Drugs Market Outlook

9. South America Generic Drugs Market Outlook

10. Middle East and Africa Generic Drugs Market Outlook

11. Market Dynamics

12. Market Trends & Developments

13. Porter's Five Forces Analysis

14. Competitive Landscape

15. Strategic Recommendations

16. About Us & Disclaimer

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â